Sprint Bioscience appoints Erik Kinnman as new CEO

Sprint Bioscience AB (publ) announces today that Erik Kinnman has been appointed new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021.

Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive), a biotechnology company listed on Nasdaq Stockholm’s Main Market. Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank. Erik Kinnman is a physician, Doctor of Medicine, and associate professor at Karolinska Institutet. He has a specialist education in neurology and pain relief, as well as an Executive MBA from the Stockholm School of Economics.

“We are very pleased to welcome Erik Kinnman as the new CEO of Sprint Bioscience. His extensive experience from leading positions in global pharmaceutical companies, solid scientific background, and thorough understanding of the capital market give him excellent qualifications to lead the company in its further development. I would also like to extend a big thank you to Charlotte Leife for her significant efforts during her time as Acting CEO”, says Sprint Biosciences’ Chairman of the Board, Rune Nordlander.

“I see great potential in Sprint Bioscience’s unique pharmaceutical project and business model, and I look forward to leading a company where employees have such strong competence and innovative power. My focus will be on optimizing the potential for current partner projects to succeed and for more collaboration agreements with international pharmaceutical companies to be concluded, as well as to ensure resource-efficient generation of new pharmaceutical projects to create significant shareholder value”, says Erik Kinnman, incoming CEO of Sprint Bioscience.

 

This disclosure contains information that Sprint Bioscience is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-02-2021 09:10 CET.

For further information, please contact:
Rune Nordlander, Chairman of the Board, Sprint Bioscience
Tel: +46-(0)733 89 68 27
Mail: rune.nordlander@first-venture.se

About Sprint Bioscience 
Sprint Bioscience (publ) develops small-molecule first-in-class drug projects with a focus on oncology. With a fragment-based drug development method, the company develops drug projects in a time- and resource-efficient way that is outlicensed to global pharmaceutical companies during the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 470 million.Sprint Bioscience is situated in Stockholm, Sweden. Sprint Bioscience share is listed on Nasdaq First North Growth Market and traded under the name SPRINT.Additional information is available on the company website; www.sprintbioscience.com.
Certified Advisor is FNCA Sweden AB ; +46 (0)8 528 00 399, info@fnca.se, www.fnca.se.

Sprint Bioscience │ Novum│141 57 Huddinge │ Sweden │ 46-(0)8-411 44 55 │info@sprintbioscience.com

Documents for download

Images attached to this press release

  • Erik Kinnman